Leo Nicolai

TL;DR: Evidence is provided that organ involvement and prothrombotic features in COVID-19 are linked by immunothrombosis, and data point to immunothROMbotic dysregulation as a key marker of disease severity in CO VID-19.

TL;DR: It is shown that adherent platelets use adhesion receptors to mechanically probe the adhesive substrate in their local microenvironment and are assigned a central role in innate immune responses and identified as potential targets to dampen inflammatory tissue damage in clinical scenarios of severe systemic infection.

TL;DR: It is shown that eosinophils support atherosclerotic plaque formation involving enhanced von Willebrand factor exposure on endothelial cell and augmented platelet adhesion and are a promising new target in the prevention and therapy of atherosclerosis and thrombosis.

TL;DR: Rivaroxaban exerts an antiplatelet effect that together with its well-known potent anticoagulatory capacity might lead to reduced frequency of atherothrombotic events and improved outcome in patients.

TL;DR: It is sought to study whether immunothrombosis is a pathognomonic factor in COVID‐19 or a general feature of (viral) pneumonia, as well as to better understand its upstream regulation.